Table 2.
Demographic and Treatment Characteristics for Matched Cohort
| Characteristic | Primary Samples (n = 152) | Metastatic Samples (n = 184) |
|---|---|---|
| Age at Time of Primary Sample, median (IQR), y | 65.8 (57.0–72.0) | - |
| Sex | ||
| Female | 100 (65.8) | - |
| Male | 52 (34.2) | |
| Race Asian |
18 (11.8) |
|
| Black | 11 (7.2) | - |
| Other | 11 (7.2) | |
| White | 112 (73.7) | |
| Smoking History | ||
| Ever | 100 (65.8) | - |
| Never | 52 (34.2) | |
| Clinical Stage I |
44 (28.9) | |
| II | 11 (7.2) | |
| III | 26 (17.1) | - |
| IV | 68 (44.7) | |
| Unknown | 3 (2.0) | |
| Treatment Prior to IMPACT Sequencing Yes |
47 (30.9) | 145 (78.8) |
| No | 105 (69.1) | 39 (21.2) |
| Type of Treatment Prior to IMPACT Sequencing Chemotherapy |
25 (16.4) | 79 (42.9) |
| Immunotherapy | 4 (2.6) | 32 (17.4) |
| Targeted Therapy | 28 (18.4) | 93 (50.5) |
| Radiation | 3 (2.0) | 37 (20.1) |
| Definitive Local Therapy for Primary | ||
| Surgery | 71 (46.7) | - |
| Radiation | 14 (9.2) |
IQR, interquartile range; IMPACT, Integrated Mutation Profiling of Actionable Cancer Targets.